search
Back to results

Effects of a Patient Portal Intervention to Address Diabetes Care Gaps

Primary Purpose

Diabetes Mellitus

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Diabetes Care Gaps Patient Portal Intervention
Sponsored by
Vanderbilt University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Diabetes Mellitus focused on measuring Diabetes Mellitus, Self-efficacy, Patient Web Portals, Health Information Technology

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Established patient with a participating primary care physician from a participating clinic
  • Type 1 or 2 diabetes mellitus
  • Able to read in English
  • Age 18 to 75 years old
  • Mobile device (smartphone or tablet) with internet access
  • Active My Health at Vanderbilt (MHAV) account

Exclusion Criteria:

  • A medical condition that prevents use of a mobile device
  • Pregnant or planning to become pregnant during the study period
  • Severe difficulty seeing
  • On dialysis

Sites / Locations

  • Vanderbilt University Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention

Usual Care

Arm Description

Patients have access to an existing patient web portal (My Health at Vanderbilt) embedded with the Diabetes Care Gaps Patient Portal Intervention. .

Patients will have access to an existing patient web portal (My Health at Vanderbilt) NOT embedded with the intervention (i.e., usual care).

Outcomes

Primary Outcome Measures

Number of Diabetes Care Gaps at 12 months
Number of diabetes care gaps per patient out of four possible: no diabetes eye exam in the last 12 months, no hemoglobin A1C blood test in the last 6 months, no urine microalbumin in the last 12 months, and no pneumococcal vaccination of any kind ( i.e., never received PPSV-23, PCV-13, PCV-15, or PCV-20) The presence of a diabetes care gap will be assessed by electronic health record (EHR) abstraction.

Secondary Outcome Measures

Number of Diabetes Care Gaps at 6 months
Number of diabetes care gaps per patient out of four possible: no diabetes eye exam in the last 12 months, no hemoglobin A1C blood test in the last 6 months, no urine microalbumin in the last 12 months, and no pneumococcal vaccination of any kind ( i.e., never received PPSV-23, PCV-13, PCV-15, or PCV-20)( The presence of a diabetes care gap will be assessed by electronic health record (EHR) abstraction
Patient Initiated Orders
The number of patient-initiated orders for evidence-based diabetes monitoring and preventative services (e.g., A1c).
Change in Understanding of Diabetes Monitoring and Preventative Care
Unique study specific items (four items) to assess participant's understanding of measures of diabetes monitoring and preventative care (e.g., Diabetes Eye Exams) will be administered to all study participants. Each multiple-choice item has only one correct answer and the overall measure is scored as the percent of the items answered correctly.
Change in Confidence toward Managing Diabetes in General
The 5-item Manage Disease in General Scale of the Chronic Disease Self-Efficacy Scales is a validated measure of the confidence a person has in managing their own health and health care and is closely related to patient activation. The items were adapted to be specific to diabetes rather than a generic condition or illness. Each item uses a 10-point Likert-type scale of response options ranging from 1 (not at all confident) to 10 (totally confident). Responses result in total raw scores ranging from 1 to 10. The score for the scale is the mean of the items. Higher scores indicate greater confidence in managing diabetes in general.
Change in Diabetes Distress
The Problem Areas in Diabetes Scale (PAID-5) is a valid measure of diabetes distress. The PAID-5 contains 5 items which have a five-point response option (0-4 representing 'Not a problem' through to 'Serious problem'). Total scores on the PAID-5 can range from 0 to 20, with higher scores suggesting greater diabetes-related emotional distress care (e.g., Diabetes Eye Exams) will be administered to all study participants.
Satisfaction/Usability of My Health at Vanderbilt
The System Usability Scale (SUS) is a valid measure of usability and assesses user's perceptions of ease of use, likability of the interface, and overall satisfaction. Each question on the 10-item questionnaire is scored on a 5-point Likert scale [0 (Strongly disagree) to 4 (strongly agree)] and the sum is totaled (0-40). The total sum is then multiplied by 2.5 to convert the original scores to a range of 0 (worst) to 100 (best). Based on prior research, a score above 68 would be above average and a score of 85 or above suggests excellent usability. The SUS has been used in several studies of patient facing health information technology (the article describing its psychometric properties has been cited over 500 times) and has excellent internal consistency reliability (Cronbach's alpha of 0.91).
Change in Blood Glucose Control
Participants' most recent hemoglobin A1C will be abstracted from participants' electronic medical record.
Treatment Intensification
The addition or increase in dose of: (a) antihyperglycemic medications and (b) antihypertensive medications will be assessed by EHR abstraction.
Change in Diabetes Self-efficacy
The Perceived Diabetes Self-Management Scale (PDSMS) is a valid measure of diabetes self-efficacy (i.e., how confident they feel about their ability to carry out multiple self management tasks). The uni-dimensional, 8-item scale is scored on a five-point Likert scale. The total PDSMS score can range from 8 to 40, with higher scores indicating more confidence in self-managing one's diabetes.
Reported Services Completed Outside Vanderbilt System
The number of reports of diabetes eye exams outside the Vanderbilt University Medical Center health system received through the study intervention.

Full Information

First Posted
May 11, 2021
Last Updated
June 6, 2023
Sponsor
Vanderbilt University Medical Center
Collaborators
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
search

1. Study Identification

Unique Protocol Identification Number
NCT04894903
Brief Title
Effects of a Patient Portal Intervention to Address Diabetes Care Gaps
Official Title
Effects of a Patient Portal Intervention to Address Diabetes Care Gaps: A Pragmatic Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
April 30, 2022 (Actual)
Primary Completion Date
February 29, 2024 (Anticipated)
Study Completion Date
February 29, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vanderbilt University Medical Center
Collaborators
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the effect of a novel patient portal intervention on the number of patients with diabetes care gaps (e.g., no diabetes eye exam i the last 12 months). The intervention is designed to: (a) notify patients when selected, clinically meaningful, evidence-based diabetes monitoring & preventative care (e.g., annual urine microalbumin) are due and (b) allow patients to initiate orders for the care.
Detailed Description
Participants will be recruited from 14 VUMC-affiliate adult primary care clinics located throughout Middle Tennessee. Patients will be randomized 1:1 to the intervention or usual care. 500 adult patients with type 1 or 2 diabetes mellitus will be assigned to one of two arms. 250 will be assigned to receive access to the intervention embedded within an existing patient web portal (My Health at Vanderbilt) at Vanderbilt University Medical Center. 250 will be assigned to a usual care comparison arm with access to the currently available version of My Health at Vanderbilt without the study intervention. At enrollment, participants will complete a baseline questionnaire and diabetes health data will be abstracted from the patients' electronic health record (EHR) before being assigned to the intervention or control arm. Participants will receive additional follow-up questionnaires and diabetes health data will be abstracted from the EHR at 3-month, 6-month, and 12-month follow-ups to assess outcomes. In addition, system usage data (user analytics) will be collected throughout the study period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus
Keywords
Diabetes Mellitus, Self-efficacy, Patient Web Portals, Health Information Technology

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
440 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Experimental
Arm Description
Patients have access to an existing patient web portal (My Health at Vanderbilt) embedded with the Diabetes Care Gaps Patient Portal Intervention. .
Arm Title
Usual Care
Arm Type
No Intervention
Arm Description
Patients will have access to an existing patient web portal (My Health at Vanderbilt) NOT embedded with the intervention (i.e., usual care).
Intervention Type
Other
Intervention Name(s)
Diabetes Care Gaps Patient Portal Intervention
Intervention Description
The Diabetes Care Gaps Patient Portal Intervention is embedded within an existing patient web portal (My Health at Vanderbilt). The intervention (a) notifies patients when selected, clinically meaningful, evidence-based diabetes monitoring & preventative care (e.g., annual urine microalbumin) are due and (b) allows patients to initiate orders for the care.
Primary Outcome Measure Information:
Title
Number of Diabetes Care Gaps at 12 months
Description
Number of diabetes care gaps per patient out of four possible: no diabetes eye exam in the last 12 months, no hemoglobin A1C blood test in the last 6 months, no urine microalbumin in the last 12 months, and no pneumococcal vaccination of any kind ( i.e., never received PPSV-23, PCV-13, PCV-15, or PCV-20) The presence of a diabetes care gap will be assessed by electronic health record (EHR) abstraction.
Time Frame
Baseline and 12-month follow-up
Secondary Outcome Measure Information:
Title
Number of Diabetes Care Gaps at 6 months
Description
Number of diabetes care gaps per patient out of four possible: no diabetes eye exam in the last 12 months, no hemoglobin A1C blood test in the last 6 months, no urine microalbumin in the last 12 months, and no pneumococcal vaccination of any kind ( i.e., never received PPSV-23, PCV-13, PCV-15, or PCV-20)( The presence of a diabetes care gap will be assessed by electronic health record (EHR) abstraction
Time Frame
Baseline and 6-month follow-up
Title
Patient Initiated Orders
Description
The number of patient-initiated orders for evidence-based diabetes monitoring and preventative services (e.g., A1c).
Time Frame
Baseline, 3-month follow-up, 6-month follow-up, and 12-month follow-up
Title
Change in Understanding of Diabetes Monitoring and Preventative Care
Description
Unique study specific items (four items) to assess participant's understanding of measures of diabetes monitoring and preventative care (e.g., Diabetes Eye Exams) will be administered to all study participants. Each multiple-choice item has only one correct answer and the overall measure is scored as the percent of the items answered correctly.
Time Frame
Baseline to 3-month follow-up, baseline to 6-month follow-up, and baseline to 12-month follow-up
Title
Change in Confidence toward Managing Diabetes in General
Description
The 5-item Manage Disease in General Scale of the Chronic Disease Self-Efficacy Scales is a validated measure of the confidence a person has in managing their own health and health care and is closely related to patient activation. The items were adapted to be specific to diabetes rather than a generic condition or illness. Each item uses a 10-point Likert-type scale of response options ranging from 1 (not at all confident) to 10 (totally confident). Responses result in total raw scores ranging from 1 to 10. The score for the scale is the mean of the items. Higher scores indicate greater confidence in managing diabetes in general.
Time Frame
Baseline to 3-month follow-up, baseline to 6-month follow-up, and baseline to 12-month follow-up
Title
Change in Diabetes Distress
Description
The Problem Areas in Diabetes Scale (PAID-5) is a valid measure of diabetes distress. The PAID-5 contains 5 items which have a five-point response option (0-4 representing 'Not a problem' through to 'Serious problem'). Total scores on the PAID-5 can range from 0 to 20, with higher scores suggesting greater diabetes-related emotional distress care (e.g., Diabetes Eye Exams) will be administered to all study participants.
Time Frame
Baseline to 3-month follow-up, baseline to 6-month follow-up, and baseline to 12-month follow-up
Title
Satisfaction/Usability of My Health at Vanderbilt
Description
The System Usability Scale (SUS) is a valid measure of usability and assesses user's perceptions of ease of use, likability of the interface, and overall satisfaction. Each question on the 10-item questionnaire is scored on a 5-point Likert scale [0 (Strongly disagree) to 4 (strongly agree)] and the sum is totaled (0-40). The total sum is then multiplied by 2.5 to convert the original scores to a range of 0 (worst) to 100 (best). Based on prior research, a score above 68 would be above average and a score of 85 or above suggests excellent usability. The SUS has been used in several studies of patient facing health information technology (the article describing its psychometric properties has been cited over 500 times) and has excellent internal consistency reliability (Cronbach's alpha of 0.91).
Time Frame
Baseline, 3-month follow-up, 6-month follow-up, and 12-month follow-up
Title
Change in Blood Glucose Control
Description
Participants' most recent hemoglobin A1C will be abstracted from participants' electronic medical record.
Time Frame
Baseline to 3-month follow-up, baseline to 6-month follow-up, and baseline to 12-month follow-up
Title
Treatment Intensification
Description
The addition or increase in dose of: (a) antihyperglycemic medications and (b) antihypertensive medications will be assessed by EHR abstraction.
Time Frame
Baseline to 3-month follow-up, baseline to 6-month follow-up, and baseline to 12-month follow-up
Title
Change in Diabetes Self-efficacy
Description
The Perceived Diabetes Self-Management Scale (PDSMS) is a valid measure of diabetes self-efficacy (i.e., how confident they feel about their ability to carry out multiple self management tasks). The uni-dimensional, 8-item scale is scored on a five-point Likert scale. The total PDSMS score can range from 8 to 40, with higher scores indicating more confidence in self-managing one's diabetes.
Time Frame
Baseline to 3-month follow-up, baseline to 6-month follow-up, and baseline to 12-month follow-up
Title
Reported Services Completed Outside Vanderbilt System
Description
The number of reports of diabetes eye exams outside the Vanderbilt University Medical Center health system received through the study intervention.
Time Frame
Baseline, 3-month follow-up, 6-month follow-up, and 12-month follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Established patient with a participating primary care physician from a participating clinic Type 1 or 2 diabetes mellitus Able to read in English Age 18 to 75 years old Mobile device (smartphone or tablet) with internet access Active My Health at Vanderbilt (MHAV) account Exclusion Criteria: A medical condition that prevents use of a mobile device Pregnant or planning to become pregnant during the study period Severe difficulty seeing On dialysis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
William Martinez, MD, MS
Organizational Affiliation
Vanderbilt University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37212
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
After study results are posted on clinical trials and published in a peer-reviewed journal, de-identified individual participant data that underlie the results reported will be available upon requests made to the principal investigator and ending after 36 months after publication.
IPD Sharing Time Frame
Deidentified individual participant data that underlie the results reported will be available after publication in a peer reviewed journal and posted on clinical trials and ending after 36 months after publication.
IPD Sharing Access Criteria
Researchers should provide a methodologically sound proposal to achieve their proposed aims. Proposals may be submitted to the principal investigator up to 36 months following publication. To gain access, data requestors will need to sign a data access agreement.

Learn more about this trial

Effects of a Patient Portal Intervention to Address Diabetes Care Gaps

We'll reach out to this number within 24 hrs